Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHODH | Q02127 | 5/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | LATS1 | O95835 | 7/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | LATS2 | Q9NRM7 | 4/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2124665 | 0.86 | KDM4C (0.50) | DHODHRORCCYP11B1CYP11B2KDM4C | |
| SCHEMBL2126711 | 0.81 | PIK3CA (0.43) | DHODHRORCLATS1KDM4CPIK3CA | |
| SCHEMBL2124508 | 0.77 | PIK3CA (0.46) | DHODHLATS1CYP2A6LATS2PIK3CA | |
| SCHEMBL2123197 | 0.74 | RORC (0.43) | DHODHRORCLATS1KDM4CLATS2 | |
| SCHEMBL2124649 | 0.72 | KDM4E (0.49) | DHODHCYP2A6PIK3CA | |
| SCHEMBL2712930 | 0.71 | CYP11B1 (0.44) | DHODHCYP11B1CYP11B2ACHE | |
| SCHEMBL2125276 | 0.70 | PIK3CA (0.45) | CYP11B1CYP11B2PTGS2CYP2A6PIK3CA | |
| SCHEMBL2124769 | 0.69 | DHODH (0.50) | DHODHRORCCYP11B1CYP11B2PIK3CA | |
| SCHEMBL2711571 | 0.69 | DHODH (0.46) | DHODHRORCCYP11B1CYP11B2 | |
| SCHEMBL2123766 | 0.68 | MAPK14 (0.52) | DHODHPIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | DHODH 2656/4885RORC 192/4885CYP11B1 1284/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.